RxDoctor Payments Data

Edwin Yu, MD

Family Medicine · Montebello, CANPI 1134220544

Payments from drug & device makers

$9,921in general payments, 2019–2025

Across 197 payments — averaging $50.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tris Pharma Inc$7K
  • Novo Nordisk$1K
  • Bayer$451
  • Merck$371
  • Lilly USA, LLC$295
  • Sumitomo Pharma America, Inc.$147
  • plus $871 from 16 others

What the payments were for

  • Speaking & faculty fees$4,50045%
  • Travel & lodging$1,26413%
  • Food & beverage$4,13842%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,921 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$34,108
Medicare patients
132
Services billed
441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin335$413,485
RybelsusSemaglutide98$179,629
FarxigaDapagliflozin Propanediol115$155,606
KerendiaFinerenone98$116,386
JanuviaSitagliptin Phosphate90$104,159
EliquisApixaban106$101,610
OzempicSemaglutide54$52,761
MyrbetriqMirabegron47$41,556
XareltoRivaroxaban28$32,937
TrulicityDulaglutide26$28,384
MounjaroTirzepatide15$22,687
TradjentaLinagliptin15$21,823
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,886
InvokanaCanagliflozin16$14,879
Combivent RespimatIpratropium/Albuterol Sulfate23$11,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$67$446,627373 claims
Novo NordiskRybelsus, Ozempic$1,163$232,390152 claims
AstraZenecaFarxiga, Brilinta$119$162,150131 claims
BayerKerendia$451$116,38698 claims
MerckJanuvia$371$104,15990 claims
PfizerEliquis$39$101,610106 claims
Lilly USA, LLCTrulicity, Mounjaro$295$51,07141 claims
GSKTrelegy Ellipta$46$14,88620 claims
AbbVieLumigan$15$3,77016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Montebello

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →